Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Peripartum

Esketamine for Peripartum

1 paper and 6 clinical trials exploring esketamine as a treatment for peripartum.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 15-20% of women experience postpartum depression worldwide.

Peripartum

Peripartum depression, including postpartum depression (PPD), is a significant mental health issue affecting new mothers, characterised by severe mood changes following childbirth. Current research into psychedelic treatments, particularly with compounds like esketamine and psilocybin, shows promising potential to alleviate depressive symptoms in this demographic.

Full Peripartum profile

Academic Research

1 paper
Open Accessindividual

Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women

This randomised controlled trial (n=136) found that a single low-dose esketamine infusion (14mg/70kg) given after fetal delivery during caesarean section, combined with patient-controlled analgesia, reduced postnatal depression scores at days 2 and 7, improved recovery quality, and shortened time to first ambulation, flatus and breastfeeding compared to placebo, with no significant difference in adverse events.

Published
February 15, 2026
Journal
American Journal of Translational Research
Authors
Jing, R., Tu, Y.

Clinical Trials

6 trials
Not yet recruitingPhase NA

Effect of a single low-dose dose of esketamine on postpartum depression and quality of recovery in women undergoing cesarean section: a prospective, randomised controlled study

This randomised, parallel-group trial (n=136) is evaluating whether a single low-dose infusion of esketamine after caesarean section can reduce postpartum depressive symptoms and improve recovery in women in China. Participants are allocated to receive intravenous esketamine 0.2 mg/kg over 40 minutes after surgery or an intravenous physiological saline infusion for the same duration as the comparator. The study is interventional and involves adult women aged 18 to 60 years undergoing caesarean delivery. The primary outcome is the Edinburgh Postnatal Depression Scale (EPDS) score, assessed on postpartum day 2 and postpartum day 7. Secondary outcomes include the Obstetric Quality of Recovery-10 (ObsQoR-10) score at 24 and 48 hours postpartum, resting and exercise pain scores measured using a visual analogue scale at 24 hours postpartum, and postpartum length of hospital stay. No phase is specified. The trial is being conducted in China and is sponsored by Dongguan Maternal and Child Health Hospital.

Started
September 1, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ChiCTR2400088992
CompletedPhase NA

The Effect of Esketamine on Sleep Disturbance

Randomised, triple-blind, parallel-group trial (n=204) testing a single 0.2 mg/kg IV esketamine injection versus 5 ml 0.9% saline in females undergoing surgical abortion with sleep disturbance.

Started
May 3, 2024
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06388824
Unknown statusPhase IV

Effects of Esketamine on Postpartum Depression

Randomised, phase IV trial (n=500) comparing four esketamine concentrations added to postoperative PCIA versus no esketamine for postpartum depression and analgesia after cesarean section.

Started
February 20, 2022
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05229913
CompletedPhase NA

Esketamine on Postpartum Depression in Cesarean Section Women

Randomised, quadruple-blind, parallel study (n=336) testing prophylactic IV esketamine (0.25 mg/kg) after cord clamp plus esketamine-supplemented PCIA versus saline to prevent postpartum depression after elective cesarean section.

Started
May 1, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04860661
Active not recruitingPhase IV

Effect of Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth

Double-blind, randomized, placebo-controlled follow-up (n=364) assessing whether a single immediate postpartum IV infusion of low-dose esketamine (0.2 mg/kg) reduces incidence of maternal depression at 2 years postpartum in women with prenatal depressive symptoms.

Started
June 19, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05698394
CompletedPhase NA

Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression

This study is designed to investigate whether low-dose s-ketamine administered after childbirth can reduce the incidence of postpartum depression in parturients with prenatal depression.

Started
June 19, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT03927378

Explore further

Search all Esketamine papers Search all Peripartum trials Full Esketamine profile Full Peripartum profile